## US Family Health Plan Prior Authorization Request Form for adalimumab ( Humira )

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 617-562-5296

OR

The patient may attach the completed form to the prescription and **mail** it to: **Attn: Pharmacy, 77 Warren St, Brighton, MA 02135** 

QUESTIONS? Call 1-877-880-7007

Step	Please complete patient and physician information (please print):						
1	Patient Name: Address:  Sponsor ID # Date of Birth:		Physician Name:Address:				
			Phone #:  Secure Fax #:				
Step 2	Please complete the clinical assessment:						
	1. Is the patient 18 years of age or older?		☐ Yes	□ No			
			proceed to question <b>7 on</b> page 2	proceed to question 2			
	2. What is the indication or diagnosis in this pediatric patient?	□ moderate to severe active proceed to question 3	polyarticular <b>juvenile idiopathic</b> 3	c arthritis –			
		□ moderately to severely active <b>Crohn's disease</b> − proceed to question <b>4</b>					
		□ Uveitis – proceed to question 5					
		□ other indication or diagnosis – STOP: Coverage not approved.					
		Please document diagnosis:					
	3. Is the patient 2 to 17 years of age? (that is, age 2 through 17 years)		□ Yes	□ No			
			proceed to question 10 on page 2	STOP Coverage not approved			
	4. Is the patient 6 years of age or older?		□ Yes	□ No			
			proceed to question 6	STOP Coverage not approved			
	5. Is the patient 2 years of age or older?		□ Yes	□ No			
			proceed to question 10 on page 2	STOP Coverage not approved			
	6. Has the patient had an inadequate response to corticosteroids, azathioprine, 6-mercaptopurine (6-MP), or methotrexate?		□ Yes	□ No			
			proceed to question 10 on page 2	STOP Coverage not approved			
			Questio	ns 6 – 11 continue on next page			

## Prior Authorization Request Form for adalimumab ( **Humira** )

	7. What is the indication or diagnosis in this	☐ moderately to severely active <b>rheumatoid arthritis</b> – go to question <b>10</b>					
		adult patient?	· · · · · · · · · · · · · · · · · · ·				
			□ active ankylosing spondylitis – go to question 8				
			☐ moderate to severe <b>chronic plaque psoriasis</b> in a patient who may benefit from				
			taking injection or pills (systemic therapy) or phototherapy – go to question 10				
			□ moderately to severely active <b>Crohn's disease</b> – go to question <b>9</b>				
			□ moderately to severely active ulcerative colitis – go to question 10				
			□ hidradenitis suppurativa – go to question <b>10</b>				
			☐ treatment of <b>uveitis</b> (non-i go to question <b>10</b>	nfectious intermediate, posterior	r and panuveitis patients)–		
			other indication or diagnos	sis – STOP: Coverage not app	proved.		
			Please document diagnosis	:			
	8.	Has the patient had an inadequate response to at least two NSAIDS over a period of at least two months?		☐ Yes – to go question 10	□ No – STOP Coverage not approved		
	9. Has the patient had an inadequate response to conventional therapy?  (for example, methotrexate, aminosalicylates [e.g.		☐ Yes – go to question 10	□ No – STOP Coverage not approved			
		sulfasalazine, mesalamin immunosuppressants [e.					
	10.		ngestive heart failure (CHF) re been reported with TNF MIRA. Is the prescriber	☐ Yes – go to question 11	□ No – STOP Coverage not approved		
	11.	Will the patient be recei immunomodulatory bio including but not limite Cimzia, Cosentyx, Enbr Kineret, Olumiant, Oren Rituxan, Siliq, Simponi, Tremfya or Xeljanz/Xelja	logics with Humira, d to the following: Actemra, el, llumya, Kevzara, icia, Otezla, Remicade, Stelara, Taltz,	☐ Yes - STOP Coverage not approved	□ No – go to question <b>12</b>		
	12.		dence of a negative TB test nths (or TB is adequately	☐ Yes – Sign and date below	□ No – Sign and date below		
Step 3	I certify the above is true to the best of my knowledge. Please sign and date:						
		Prescrit	per Signature	Date			
					[0.0 No 0.04.0]		

[23 November 2018]